Pembrolizumab and other immunotherapies in patients with extensive-stage small-cell lung cancer—are we entering a new era?

Small cell lung cancer (SCLC) is a very lethal and aggressive subtype of lung cancer, responsible for about 15% of all lung cancers (1).